큐라 온콜로지(KURA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $11.78 (+0.51%), 시가총액 $0.78B, 52주 최저~최고 $5.54 ~ $12.14.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
큐라 온콜로지의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
큐라 온콜로지의 현재 주가는 $11.78 (+0.51%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
큐라 온콜로지의 시가총액은 약 $0.78B입니다.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, rev